Loading news...
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma's integrated SLNB test result.
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the predicted SLN positivity rate is less than 5%.
Castle will share new data evaluating DecisionDx-Melanoma's i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time.
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $31.88, but opened at $29.87. Castle Biosciences shares last traded at $30.2290, with a volume of 212,078 shares. Key Stories Impacting Castle Biosciences Here are the key news stories impacting
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.32 per share a year ago.
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.
FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology (JAAD) demonstrating that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis (AD) who are significantly more likely to achieve greater and faster clinical responses when treated with a Janus kinase inhibitor (JAKi) compared to T helper type 2 (Th2)-targeted therapies.1 “Atopic dermatitis can look similar on the surface, but the biology driving the disease can differ meaningfully from patient to patient,” said Mark G. Lebwohl, M.D.
Castle Biosciences (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences (CSTL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m.
Allspring Emerging Growth Fund Q4 2025 Performance Review
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Derek Maetzold sold 4,017 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the sale, the insider owned 87,715 shares in the company, valued at
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Campbell and CO Investment Adviser LLC bought a new stake in shares of Castle Biosciences, Inc. (NASDAQ: CSTL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,996 shares of the company's stock, valued at approximately $615,000. Campbell and CO Investment Adviser LLC
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on
Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.